Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19294594 | VARIANT STRAIN-BASED CORONAVIRUS VACCINES | August 2025 | March 2026 | Allow | 7 | 1 | 1 | Yes | No |
| 18733214 | IMMUNOGENIC TRIMERS | June 2024 | December 2025 | Allow | 19 | 2 | 0 | No | No |
| 18680137 | METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18675059 | CHIKUNGUNYA VIRUS (CHIKV) VIRUS-LIKE PARTICLES (VLPS) COMPRISING THE C, E1, AND E2 STRUCTURAL PROTEINS | May 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
| 18649467 | A549 HOST CELLS COMPRISING A RECOMBINANT ONCOLYTIC ADENOVIRUS WITH MODIFIED E1A CANCER-SPECIFIC PROMOTER | April 2024 | December 2024 | Allow | 8 | 0 | 0 | No | No |
| 18597488 | METHOD FOR IMPROVING RETROVIRAL TRANSDUCTION AND GENE EDITING IN HEMATOPOIETIC STEM CELLS USING CLYCLOSPORIN H AND UM171 | March 2024 | August 2025 | Allow | 17 | 2 | 0 | No | No |
| 18444033 | METHOD FOR KILLING HIV-INFECTED CELLS USING BCL-2 INHIBITORS | February 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18292949 | ENHANCED EXPRESSION OF POLO-LIKE KINASE 3 (PLK3) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED CELLS | January 2024 | December 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18402480 | METHODS OF ELICITING ANTIBODIES THAT BIND TO FULL-LENGTH GLYCOSYLATED HIV-1 ENV USING MULTIMERIZED ENV CORES | January 2024 | October 2025 | Allow | 21 | 2 | 0 | No | No |
| 18396370 | Vaccine Compositions For Preventing Coronavirus Disease | December 2023 | January 2026 | Abandon | 25 | 0 | 1 | No | No |
| 18394555 | REPLICATION-DEFICIENT MODIFIED VACCINIA ANKARA (MVA) EXPRESSING MARBURG VIRUS GLYCOPROTEIN (GP) AND MATRIX PROTEIN (VP40) | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18392147 | ARENAVIRUS MONOCLONAL ANTIBODIES AND USES | December 2023 | April 2025 | Allow | 16 | 1 | 1 | No | No |
| 18385250 | METHOD OF TREATING TUMORS COMPRISING ADMINISTERING A LYMPHOCYTIC CHORIOMENINGTITIS VIRUS (LCMV) WITH IMPROVED TUMOR REGRESSION PROPERTIES | October 2023 | May 2025 | Allow | 19 | 1 | 1 | No | No |
| 18488629 | SARS-COV-2 VACCINES COMPRISING HUMAN ADENOVIRUS VECTORS ENCODING SPIKE AND NUCLEOCAPSID-ETSD IMMUNOGENS | October 2023 | February 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18454011 | ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18452002 | METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES | August 2023 | May 2025 | Allow | 21 | 2 | 1 | No | No |
| 18449739 | COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18352657 | ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINE AND RELATED METHODS | July 2023 | September 2025 | Allow | 26 | 3 | 0 | Yes | No |
| 18212606 | METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION | June 2023 | October 2025 | Allow | 28 | 2 | 1 | No | No |
| 18312532 | METHODS FOR THE TREATMENT OF COVID-19 COMPRISING ADMINSTERING REPLICATION- DEFECTIVE ADENOVIRUSES ENCODING THE SARS-COV-2 SPIKE GLYCOPROTEIN AND MODIFIED NUCLEOCAPSID PROTEIN | May 2023 | November 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18297301 | BROADLY NEUTRALIZING ANTIBODIES THAT TARGET HIV ENV V3 N-GLYCANS | April 2023 | February 2025 | Allow | 23 | 1 | 1 | No | No |
| 18041295 | SAMPLE PREPARATION AND VIRAL DETECTION METHODS | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18153667 | RECOMBINANT BOVINE IMMUNODEFICIENCY VIRUS-LIKE PARTICLES COMPRISING AN INFLUENZA HA TRANSMEMBRANE DOMAIN AND C-TERMINUS | January 2023 | January 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 17925308 | NUCLEIC ACID AMPLIFICATION ASSAY USING 3-D MAGNETIC RESONANCE IMAGING DETECTION FOR SCREENING LARGE POPULATIONS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18054594 | NOVEL MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18049552 | POINT-OF-CARE SARS-COV-2 VIRUS DIAGNOSTIC DEVICE AND METHODS OF USE THEREOF | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17917512 | RAPID DETECTION OF VIRAL INFECTION USING RT-PCR | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17959168 | COMPOSITIONS AND METHODS FOR DETERMINING RESISTANCE TO INHIBITORS OF VIRUS ENTRY USING RECOMBINANT VIRUS ASSAYS | October 2022 | December 2024 | Allow | 26 | 2 | 0 | No | No |
| 17916647 | GENOME INTEGRITY ANALYSIS OF ADENO-ASSOCIATED VIRUS VECTORS | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17883189 | METHOD AND COMPOSITION FOR DETERMINING SPECIFIC ANTIBODY RESPONSES TO SPECIES OF FILOVIRUS | August 2022 | November 2025 | Allow | 40 | 4 | 1 | Yes | No |
| 17817301 | ENGINEERED IMMUNE-MOBILIZING T-CELL RECEPTORS WITH ENHANCED AFFINITY FOR HIV-1 GAG | August 2022 | October 2025 | Allow | 38 | 3 | 1 | No | No |
| 17816708 | FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY | August 2022 | April 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17866261 | TAT-INDUCED CRISPR/ENDONUCLEASE-BASED GENE EDITING | July 2022 | November 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17851813 | INACTIVATED VACCINE FOR CHIKUNGUNYA VIRUS | June 2022 | November 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17779510 | NOVEL AAV3B VARIANTS THAT TARGET HEPATOCYTES AND EVADE THE HUMORAL IMMUNE RESPONSE | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17749044 | NEUTRALIZING ANTIBODIES THAT BIND TO THE ZIKA VIRUS DOMAIN III ENVELOPE REGION | May 2022 | August 2024 | Allow | 27 | 2 | 0 | No | No |
| 17745723 | COMPOSITIONS AND METHODS FOR TREATING LONG COVID | May 2022 | October 2025 | Abandon | 41 | 3 | 1 | Yes | Yes |
| 17724526 | PRIMER SET OF LAMP-LFD VISUAL DETECTION FOR DETECTING LEAF CURL VIRUS OF MELIA AZEDAEACHL AND DETECTION METHOD | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17754211 | Novel Vectors and Uses Thereof | March 2022 | December 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17672871 | ANTI-CHIKV ANTIBODIES AND USES THEREOF | February 2022 | October 2024 | Allow | 32 | 2 | 1 | No | No |
| 17610040 | METHOD OF INDUCING AN HIV-1-SPECIFIC IMMUNE RESPONSE USING A CHIMPANZEE ADENOVIRUS VECTOR ENCODING AN HIVACAT T-CELL IMMUNOGEN AND TLR7 AGONIST | November 2021 | December 2025 | Allow | 49 | 2 | 0 | No | No |
| 17516172 | CHARACTERIZATION OF IMPURITIES IN ADENO-ASSOCIATED VIRUS (AAV) SAMPLES AND FORMULATION COMPOSITIONS TO STABILIZE AAV | November 2021 | December 2025 | Allow | 49 | 1 | 1 | No | No |
| 17594576 | RECOMBINANT INFLUENZA ANTIGENS | October 2021 | January 2026 | Allow | 51 | 2 | 1 | No | No |
| 17500171 | HIV-1 GP120 CD4 BINDING SITE ANTIBODIES TARGETING HIV ESCAPE MUTANTS | October 2021 | August 2024 | Allow | 34 | 1 | 1 | No | No |
| 17497354 | Method for Restoring Immune Tolerance In Vivo | October 2021 | January 2026 | Abandon | 51 | 1 | 1 | No | No |
| 17441177 | FLOW CYTOMETRY EVALUATION FOR UNASSOCIATED NON-ENVELOPED VIRAL PARTICLES | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17471573 | Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor | September 2021 | November 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17470463 | MODIFIED HIV-1 PROVIRAL VECTORS WITH ENHANCED DENDRITIC CELL TRANSDUCTION EFFICIENCIES COMPRISING THE JRFL ENVELOPE | September 2021 | August 2025 | Allow | 47 | 3 | 1 | No | No |
| 17468639 | Toilet Wastewater Collection and Testing | September 2021 | May 2025 | Abandon | 44 | 0 | 2 | No | No |
| 17310832 | KAWASAKI DISEASE ANTIBODIES IDENTIFY HEPACIVIRUS PEPTIDES | August 2021 | July 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17409260 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | August 2021 | March 2024 | Allow | 31 | 1 | 1 | No | No |
| 17405393 | METHOD OF INDUCING IMMUNITY AGAINST SARS-COV-2 USING SPIKE AND NUCLEOCAPSID-ETSD IMMUNOGENS DELIVERED BY RNA AND REPLICATION-DEFECTIVE ADENOVIRUSES | August 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17431070 | RECOMBINANT INFLUENZA VIRUSES COMPRISING TRUNCATED NS1 FUSION PROTEINS | August 2021 | November 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17399501 | IMMUNOGENIC TRIMERS | August 2021 | January 2026 | Allow | 53 | 5 | 1 | No | No |
| 17429965 | STABILIZED LIVE ATTENUATED INFLUENZA VACCINE COMPOSITIONS | August 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17429196 | A MONOPHOSPHORYL LIPID-A LIPOSOME BASED CANCER VACCINE | August 2021 | February 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17429235 | METHOD FOR T CELL ACTIVATION FOR CANCER TREATMENT | August 2021 | March 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17429206 | METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1) ASSOCIATED DISEASES | August 2021 | November 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17444223 | DETECTION OF ANTIBODIES TO SARSR-COV | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17390252 | METHODS FOR ASSESSING VIRAL CLEARANCE | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17425944 | RECOMBINANT HIGH GROWTH RATE INFLUENZA VIRUS COMPRISING MUTATIONS IN M1, NS2, AND PB2 | July 2021 | March 2025 | Allow | 43 | 2 | 0 | No | No |
| 17425309 | METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS | July 2021 | September 2025 | Allow | 50 | 1 | 1 | No | No |
| 17418974 | ADAPTED ENTEROVIRUS D68 THAT PROPAGATES TO HIGH TITER IN VERO CELLS | June 2021 | January 2025 | Allow | 42 | 0 | 1 | No | No |
| 17417893 | THERMOSTABLE COMPOSITIONS COMPRISING LIVE ATTENUATED HERPES SIMPLEX VIRUS TYPE 1 | June 2021 | March 2025 | Allow | 45 | 1 | 1 | No | No |
| 17417596 | METHOD FOR THE EXPANSION OF HPV IMMUNOGEN SPECIFIC T-CELLS | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17416642 | METHODS OF INDUCING AN IMMUNE RESPONSE | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17314255 | METHOD FOR THE EVALUATION OF ANTIRETROVIRAL THERAPY (ART) EFFECTIVENESS IN HIV-1 CD4+CD89+ CELLULAR RESERVOIRS | May 2021 | August 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17289900 | METHOD OF LABELLING VIRAL PARTICLES COMPRISING ANIONIC LIPIDS WITH FLUORESCENTLY-LABELLED NEGATIVELY-CHARGED POLYNUCLEOTIDES IN THE PRESENCE OF POLYVALENT CATIONS | April 2021 | December 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17285956 | MULTISPECIFIC ANTIBODIES TARGETING MULTIPLE EPITOPES ON THE HIV-1 ENVELOPE | April 2021 | March 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17232666 | ALPHAVIRUS REPLICON ENCODING CHIMERIC SARS-COV-2 RECEPTOR BINDING DOMAINS | April 2021 | December 2024 | Allow | 44 | 4 | 1 | No | No |
| 17283471 | METHOD OF INHIBITING GRAM-NEGATIVE BACTERIAL QUORUM SIGNALLING MOLECULES USING THE MACROCYCLE PILLAR[5]ARENE | April 2021 | June 2025 | Allow | 51 | 2 | 1 | No | No |
| 17281933 | ENGINEERED HIV-1 ENVELOPE IMMUNOGENS DESIGNED TO BIND TO PRECURSORS AND UNMUTATED COMMON ANCESTORS OF BROADLY NEUTRALIZING ANTIBODIES | March 2021 | August 2024 | Allow | 40 | 0 | 1 | No | No |
| 17281918 | HIV-1 ENVELOPE STABILIZING MUTATIONS | March 2021 | June 2024 | Allow | 39 | 1 | 1 | No | No |
| 17188813 | METHODS OF ACTIVATING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS USING AMPHIPHILIC LIGAND CONJUGATES COMPRISING CAR-TARGETING PROTEIN SEQUENCE MOTIFS | March 2021 | June 2025 | Allow | 51 | 1 | 2 | No | No |
| 17271888 | NUCLEIC ACIDS ENCODING HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) ENVELOPE PROTEINS CONTAINING MODIFIED IMMUNOSUPPRESSIVE DOMAINS (ISD) AND USES THEREOF | February 2021 | April 2025 | Allow | 49 | 3 | 1 | No | No |
| 17180147 | REPLICATION-COMPETENT ATTENUATED CHIMERIC VSV VECTORS ENCODING IMMUNOGENIC SARS-COV-2 SPIKE PROTEINS | February 2021 | January 2025 | Allow | 47 | 4 | 1 | No | No |
| 17267392 | REPLICATION-COMPETENT RECOMBINANT HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) COMPRISING DELETIONS IN THE ICP6 AND IR REGIONS | February 2021 | December 2025 | Allow | 58 | 3 | 0 | No | No |
| 16964809 | ANTIGEN-SURFACE-COUPLED LIPOSOME VACCINE FOR NON-HUMAN ANIMALS | January 2021 | November 2024 | Allow | 52 | 2 | 0 | No | No |
| 17258581 | ANTI-TUMOR COMPOSITION | January 2021 | January 2026 | Allow | 60 | 3 | 1 | No | No |
| 17252335 | COMBINATORIAL GENE THERAPY | December 2020 | March 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17114432 | ONCOLYTIC RHABDOVIRUS | December 2020 | October 2025 | Abandon | 58 | 2 | 0 | No | Yes |
| 16952016 | DUAL-AAV VECTOR-BASED SYSTEMS AND METHODS FOR DELIVERING OVERSIZED GENES TO MAMMALIAN CELLS | November 2020 | February 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17067496 | ONCOLYTIC ADENOVIRUS WITH ENHANCED REPLICATION PROPERTIES COMPRISING MODIFICATIONS IN E1A, E3, AND E4 | October 2020 | February 2025 | Allow | 52 | 1 | 1 | No | No |
| 17041787 | NUCLEIC ACID-BASED THERAPEUTICS | September 2020 | September 2025 | Abandon | 59 | 2 | 1 | No | No |
| 16975782 | USING INFECTIOUS NUCLEIC ACID TO TREAT CANCER | August 2020 | May 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16760869 | ADAPTER-BASED RETROVIRAL VECTOR SYSTEM FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS | April 2020 | March 2025 | Allow | 59 | 3 | 0 | No | Yes |
| 16838264 | METHOD OF INHIBITING ENVELOPED VIRUS BINDING TO TARGET CELLS BY INCORPORATING P-SELECTIN GLYCOPROTEIN LIGAND-1 (PSGL-1) INTO VIRIONS | April 2020 | June 2024 | Allow | 50 | 5 | 1 | Yes | No |
| 16647082 | DNA-ENCODED MONOCLONAL ANTIBODIES TARGETING THE EBOLAVIRUS GLYCOPROTEIN | March 2020 | July 2024 | Allow | 53 | 4 | 1 | No | No |
| 16787870 | METHODS AND COMPOSITIONS FOR PROTECTION AGAINST LENTIVIRAL INFECTIONS | February 2020 | September 2024 | Allow | 55 | 2 | 0 | No | No |
| 16636141 | NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY | February 2020 | August 2024 | Allow | 54 | 5 | 0 | Yes | No |
| 16607980 | SELF-INACTIVATING RABIES VIRUS VECTOR ENCODING A NUCLEOPROTEIN AND DEGRON | October 2019 | October 2024 | Allow | 59 | 3 | 1 | No | No |
| 16494843 | VLP-BASED MONOVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME | September 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16476529 | HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP | July 2019 | March 2026 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16337900 | METHOD FOR PREPARING MULTIMERIC FORMS OF THE HEPATITIS C VIRUS (HCV) ENVELOPE GLYCOPROTEIN 2 (HCV E2) | March 2019 | August 2022 | Abandon | 40 | 4 | 1 | Yes | No |
| 16087146 | CHIKUNGUNYA VIRUS CODELIVERY IMMUNIZING COMPOSITION COMPRISING DNAS ENCODING ANTI-CHIKV ENVELOPE MONOCLONAL ANTIBODY AND CHIKV ENVELOPE | September 2018 | January 2026 | Allow | 60 | 8 | 1 | No | No |
| 15783675 | CHIMERIC DENGUE VIRUS E GLYCOPROTEINS COMPRISING MUTANT DOMAIN I AND DOMAIN II HINGE REGIONS | October 2017 | June 2018 | Allow | 9 | 0 | 0 | No | No |
| 15504928 | SUBSTITUTION MONOTHERAPY TREATMENT FOR HIV-1 INFECTION EMPLOYING ANTIBODY PRO140 | June 2017 | October 2019 | Allow | 32 | 2 | 0 | No | No |
| 15426055 | Direct Method for providing Immunological Memory against HIV | February 2017 | July 2023 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 15339225 | CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES | October 2016 | October 2019 | Allow | 35 | 3 | 0 | No | No |
| 15264926 | DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES | September 2016 | June 2018 | Allow | 21 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PARKIN, JEFFREY S.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PARKIN, JEFFREY S works in Art Unit 1671 and has examined 260 patent applications in our dataset. With an allowance rate of 90.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner PARKIN, JEFFREY S's allowance rate of 90.4% places them in the 74% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by PARKIN, JEFFREY S receive 2.32 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PARKIN, JEFFREY S is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.3% benefit to allowance rate for applications examined by PARKIN, JEFFREY S. This interview benefit is in the 17% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 36.3% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 92.1% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 85.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.8% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 25.4% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.6% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.